The Home of the 4 Hour Investor Grade Business Plan. Faster investor quality documentation using HyperQuestions. I would like to convey my appreciation to you for the timely assistance provided to many of our students that helped them obtain an educational loan for studying at. As a civil wrong. In common law jurisdictions, as a civil wrong, fraud is a tort. While the precise definitions and requirements of proof vary among jurisdictions. Sss Stock Investment Loan Program' title='Sss Stock Investment Loan Program' />Im a financial editor with a proven track record of identifying stocks that significantly outperform the market. My investment advice can be found in Forbes. In. Play from Briefing. Download Film Semi Korea Lies'>Download Film Semi Korea Lies. Theravance calls for redemption of 1. Convertible Subordinated Notes due 2. THRX Co announced that it has called for redemption all of its outstanding 3 Convertible Subordinated Notes due 2. Notes. Any 2. 01. Notes outstanding on July 5, 2. The 2. 01. 5 Notes are convertible at any time prior to 5 0. SSS starts releasing of 13th month, December pension Staterun Social Security System SSS said more than 2. Application no. bar code date received received by part i employee to fill in all items ss number loan type tin name of member address no. C448' alt='Sss Stock Investment Loan Program' title='Sss Stock Investment Loan Program' />Eastern time on July 3, 2. Theravances common stock at a conversion rate of 3. On June 3, 2. 01. Theravances common stock was 3. Air Lease announces the placement of two new ATR 7. Golden Myanmar Airlines AL  4 3. Territorial Bancorp adopts fourth repurchase program of 5. TBNK Co announces that its Board of Directors has adopted a fourth stock repurchase program. Under this repurchase program, the Company may repurchase up to 5. AVEO Pharma announces strategic restructuring does not expect tivozanib to receive FDA approval to hold conference call at 8 3. ET on Wednesday, June 5 AVEO Co announced a strategic restructuring that will refocus the companys efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advancing key pipeline and preclinical assets. This restructuring is expected to extend the companys cash runway for at least two years, which is beyond anticipated data read outs from ongoing trials of tivozanib and AV 2. The AVEO management team will host a conference call at 8 3. ET on Wednesday, June 5 to discuss the restructuring and strategic direction of the company in more detail. As a result of the recent ODAC meeting, we believe that it is likely that tivozanib will not receive FDA approval for renal cell carcinoma or RCC, said William J. Slichenmyer, M. D., chief medical officer of AVEO. Gold Font Psd Download more. With the decision of our partner, Astellas, not to proceed with a European filing for tivozanib or financially support future clinical trials in RCC, AVEO has no plans at this time to pursue tivozanib development in RCC. We deeply regret the impact that this decision may have on the RCC community and wish to express our sincere gratitude to the patients and their families, investigators and nurses who have participated in our trials and supported the development of tivozanib in RCC. Tivozanib will continue to be available to those patients who remain on therapy. The company intends to focus its R D efforts on areas in oncology where the unique insights derived from AVEOs proprietary Human Response Platform will allow the development of targeted agents with the potential to provide substantial clinical benefit for specific biomarker defined patient populations that could enable a clear regulatory pathway to approval, said Tuan Ha Ngoc, president and chief executive officer of AVEO. Development update AVEO and Astellas are continuing the BATON Phase 2 clinical trials of tivozanib in breast and colorectal cancer. AVEO intends to continue the development of AV 2. ERBB3 HER3 inhibitory antibody candidate, currently in Phase 1 with expansion cohorts in specific biomarker defined patient populations. As previously announced, the company intends to focus its efforts on further ficlatuzumab development through external collaborations at this time. Ficlatuzumab is a potent hepatocyte growth factor HGF inhibitory antibody that blocks the HGFc Met pathway by binding to the HGF ligand with high affinity and specificity. Restructuring and Reogranization AVEOs strategic restructuring will eliminate approximately 1. AVEOs workforce, across the company. Separately, Elan Ezickson, executive vice president and chief operating officer of AVEO, has informed the company that after a transition period, he will resign effective July 3. Updated Financial Guidance AVEO ended the first quarter of 2. Based on its revised operating plans, AVEO expects to realize cost reductions of approximately 1. With this restructuring, AVEO expects that its current cash and marketable securities are sufficient to fund operations for at least two years. Marketaxess announces monthly volume statistics for May 2. MKTX Co announced total monthly trading volume for May 2. U. S. high grade volume, 1. This data can be accessed on Market. Axess website at www. Mitcham Ind misses by 0. MIND Reports Q1 Apr earnings of 0. Capital IQ Consensus Estimate of 0. Exa beats by 0. 0. Q2 revs in line reaffirms FY1. EXA Reports Q1 Apr adj. Pdf Cerita Bergambar'>Pdf Cerita Bergambar. Capital IQ Consensus Estimate of 0. License revenue was 1. Project revenue was 1. Co issues in line guidance for Q2, sees Q2 revs of 1. Capital IQ Consensus Estimate. Non GAAP net loss is expected to be in the range of 0. Co reaffirms guidance for FY1. FY1. 4 revs of 5. Capital IQ Consensus Estimate. Non GAAP net income is expected to be in the range of 0. Revenue in the first quarter was at the high end of our guidance, increasing 1. With the return of customer spending materializing, we are beginning to see the results of investments that we made over the last several quarters in our field organization. We are particularly encouraged by the strong growth of 4. While certain vertical markets and geographies continue to face economic challenges, overall we have seen an improvement in product development activity among our customer base. With simulation solutions that can replace the need for costly prototypes, we remain confident in our ability to see sequential improvements in year over year top line growth as we progress through the remainder of fiscal 2. OCZ Tech announces settlement of shareholder derivative litigation OCZ Co announces that it has reached a settlement in principle of federal shareholder derivative litigation filed in connection with the Companys previously announced financial restatement. The settlement is subject to negotiation of final documentation. It is also subject to court approval. The settlement will be funded by the Companys D O liability insurance and will not require any payments by the Company. This settlement does not resolve separate consolidated shareholder class actions pending in connection with the restatement. Saba Software NASDAQ announced it will delist the common stock of Saba Software and Wireless Ronin Technologies RNIN SABA NASDAQ announced that it will delist the common stock of Saba Software. Saba Softwares stock was suspended on April 0. NASDAQ since that time. Also, NASDAQ announced that it will delist the common stock of Wireless Ronin Technologies RNIN. Wireless Ronin Technologies stock was suspended on May 3. NASDAQ since that time. Bazaarvoice beats by 0. BV Reports Q4 Apr loss of 0. Capital IQ Consensus Estimate of 0. Fidelity Southern announces 6. LION The co intends to use the net proceeds from this offering, together with its cash on hand as necessary, to i redeem the 4. Fixed Rate Cumulative Perpetual Preferred Stock, Series A, originally issued to the U. S. Department of the Treasury under the Troubled Asset Relief Program Capital Purchase Program and ii redeem the two series of its fixed rate trust preferred securities with an aggregate outstanding principal amount of 2. The co intends to use any remaining net proceeds for general corporate purposes. Keefe, Bruyette Woods, a Stifel company, and Robert W. Baird Co. are the joint book running managers in the offering. FIG Partners is acting as co manager for the offering. Ambarella beats by 0. AMBA Reports Q1 Apr earnings of 0. Capital IQ Consensus Estimate of 0. Gross margin on a non GAAP basis for the first quarter of fiscal 2.